Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-09-12
2006-09-12
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S468000
Reexamination Certificate
active
07105563
ABSTRACT:
Indolinone derivatives, such as compounds of the formula (I):wherein A, m, n, R1, R2, R3, R5and R6are described herein, are disclosed herein as being useful in treating mammal having disease-states alleviated by the inhibition of PDK-1 activity.
REFERENCES:
patent: 5792783 (1998-08-01), Tang et al.
patent: 5854206 (1998-12-01), Twardzik et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 2004/0204407 (2004-10-01), Tang et al.
patent: 2004/0266843 (2004-12-01), Howlett et al.
patent: WO96/40116 (1996-12-01), None
patent: WO99/61422 (1999-12-01), None
patent: WO00/35906 (2000-06-01), None
patent: WO00/35909 (2000-06-01), None
patent: WO00/35920 (2000-06-01), None
patent: WO00/35921 (2000-06-01), None
patent: WO00/56709 (2000-09-01), None
patent: WO01/49287 (2001-07-01), None
patent: WO01/83450 (2001-11-01), None
patent: WO02/66463 (2002-08-01), None
patent: WO03/022815 (2003-03-01), None
patent: WO03/31438 (2003-04-01), None
patent: WO03/051838 (2003-06-01), None
patent: WO03/057690 (2003-07-01), None
patent: WO03/064397 (2003-08-01), None
patent: WO2004/048343 (2004-06-01), None
patent: WO2004/111008 (2004-12-01), None
Tang et al., STN International (2005), HCAPLUS Database, Accession No. 129:175549, Reg. No. 91822-51-4).
Howlett et al., STN International (2005), HCAPLUS Database, Columbus, OH, Accession No. 2005:2190.
Vanhaesebroeck, B. and D. R. Alessi, “The P13K-PDK1 connection: more than just a road to PKB,”Biochem J. (2000), vol. 346 (pt 3), pp. 561-576.
Besson, A. et al., “PTEN/MMAC1/TEP1 in signal transduction and tumorigenesis,”Eur. J. Biochem. (1999), vol. 263, No. 3, pp. 605-611.
Myers, M.P. et al., “The lipid phosphate activity of PTEN is critical for its tumor suppressor function,”Proc. Natl. Acad. Sci. USA(1998), vol. 95, No. 23, pp. 13513-13518.
Stambolic, V. et al., “Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN,”Cell(1998), vol. 95, No. 1, pp. 29-39.
Testa, J.R. and A. Bellacosa, “AKT plays a central role in tumorigenesis,”Proc. Natl. Acad. Sci. USA(2001), vol. 98, No. 20, pp. 10983-10985.
Vivanco, I. And C. L. Sawyers, “The phosphatidylinositol 3-Kinase AKT pathway in human cancer,”Nat'l Rev. Cancer(2002), vol. 2, No. 7, pp. 489-501.
Datta, S. R. et al., “Cellular survival: a play in three Akts,”Genes Dev.(1999), vol. 13, No. 22, pp. 2905-2927.
Holland, E. C. et al., “Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice,”Nat. Genet.(2000), vol. 25, No. 1, pp. 55-57.
Dimmeler, S. and A. M. Zeiher, “Akt takes center stage in angiogenesis signaling,”Circ. Res.(2000), vol. 86, No. 1, pp. 4-5.
Shiojima, I. and K. Walsh, “Role of Akt signaling in vascular homeostasis and angiogenesis,”Circ. Res.(2002), vol. 90, No. 12, pp. 1243-1250.
Inoki, K. et al., “TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling,”Nat. Cell. Biol.(2002), vol. 4, No. 9, pp. 648-657.
Potter, C. J. et al., “Akt regulates growth by directly phosphorylating Tsc2,”Nat. Cell. Biol.(2002), vol. 4, No. 9, pp. 658-665.
Alessi, D. R. et al., “3-Phosphoinositide-dependent protein kinase 1 (PDK1) phosphorylates and activates the p70 S6 kinase in vivo and in vitro,”Curr. Biol.(1998), vol. 8, No. 2, pp. 69-81.
Page, C. et al., “Overexpression of Akt/AKT can modulate chemothreapy-induced apoptosis,”Anticancer Res.(2000), vol. 20, No. 1A, pp. 407-416.
Brognard, J. et al., “Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation,”Cancer Res.(2001), vol. 61, No. 10, pp. 3986-3997.
Cantrell, D., “Protein kinase B (Akt) regulation and function in T lymphocytes,”Semin. Immunol.(2002), vol. 14, No. 1, pp. 19-26.
Kato, M. et al., “Pyrrole Butyric Acid Derivatives as Inhibitors of Steroid 5α-Reductase,”Chem. Pharm. Bull.(1997), vol. 45, No. 11, p. 1767.
Loader, C. et al., “Pyrrole chemistry. XXIII. The Cyanation of substituted pyrroles with chlorosulfonyl isocyanate (CSI). New synthesis of pyrrole-3-carbonitriles,”Can. J. Chem.(1981), vol. 59, p. 2673.
Sonnet, P. E., “Synthesis of β-Substituted Pyrroles via 1-(Pyrrol-2-ylmethylene)pyrrolidinium Salts,”J. Org. Chem., (1971), vol. 36, p. 1005.
Miyayra, N. and Suzuki, A., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds,”Chem. Rev.(1995), vol. 95, p. 2457.
Archibald, J. L. et al., “Benzamidopiperidines.2. Heterocyclic Compounds Related to Indoramin,”J. Med. Chem.(1974), vol. 17, pp. 736-739.
Alezzi, D. R. et al., “Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B,”Curr. Biol.(1997), vol. 7, pp. 261-269.
Arnaiz Damian
Bryant Judi
Chou Yuo-Ling
Feldman Richard
Hrvatin Paul
Berlex Inc.
Freistein Andrew B.
Hermenau Ronald S.
Larso Jacqueline S.
Saeed Kamal A.
LandOfFree
Indolinone derivatives and their use in treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indolinone derivatives and their use in treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone derivatives and their use in treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3605624